 Margaret Macy
Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 8 | 2023 | 130 | 2.420 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 1360 | 1.100 |
Why?
| | Neoplasms | 13 | 2023 | 2114 | 0.980 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2022 | 666 | 0.890 |
Why?
| | Protein Kinase Inhibitors | 5 | 2023 | 789 | 0.780 |
Why?
| | Glycolipids | 1 | 2021 | 37 | 0.780 |
Why?
| | Central Nervous System Neoplasms | 2 | 2019 | 125 | 0.740 |
Why?
| | Glioma | 4 | 2022 | 296 | 0.720 |
Why?
| | Radiation Injuries | 2 | 2019 | 128 | 0.700 |
Why?
| | Indazoles | 2 | 2022 | 58 | 0.680 |
Why?
| | Bevacizumab | 2 | 2019 | 118 | 0.670 |
Why?
| | Benzamides | 2 | 2022 | 169 | 0.660 |
Why?
| | Astrocytoma | 2 | 2017 | 108 | 0.650 |
Why?
| | Brain Stem Neoplasms | 2 | 2017 | 86 | 0.650 |
Why?
| | Radiotherapy | 1 | 2019 | 177 | 0.630 |
Why?
| | Chemoradiotherapy | 2 | 2017 | 187 | 0.620 |
Why?
| | Brain Diseases | 1 | 2019 | 127 | 0.620 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2022 | 225 | 0.600 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 216 | 0.600 |
Why?
| | Brain Neoplasms | 5 | 2022 | 979 | 0.500 |
Why?
| | Sarcoma | 2 | 2015 | 137 | 0.470 |
Why?
| | Child, Preschool | 20 | 2023 | 9164 | 0.430 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2023 | 862 | 0.420 |
Why?
| | Child | 30 | 2023 | 18537 | 0.420 |
Why?
| | Biomarkers, Tumor | 4 | 2022 | 1045 | 0.390 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2012 | 60 | 0.380 |
Why?
| | Quinazolines | 2 | 2023 | 241 | 0.380 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2010 | 23 | 0.370 |
Why?
| | Prognosis | 9 | 2023 | 3344 | 0.360 |
Why?
| | Antineoplastic Agents | 7 | 2020 | 1891 | 0.360 |
Why?
| | Adolescent | 22 | 2023 | 17935 | 0.340 |
Why?
| | Glioblastoma | 1 | 2012 | 251 | 0.340 |
Why?
| | Piperidines | 1 | 2010 | 163 | 0.330 |
Why?
| | Leukemia | 1 | 2010 | 207 | 0.310 |
Why?
| | DNA Damage | 1 | 2010 | 356 | 0.310 |
Why?
| | Liver Neoplasms | 1 | 2012 | 521 | 0.300 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2019 | 638 | 0.290 |
Why?
| | 3-Iodobenzylguanidine | 2 | 2023 | 6 | 0.270 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1550 | 0.260 |
Why?
| | Humans | 38 | 2023 | 115859 | 0.260 |
Why?
| | Camptothecin | 2 | 2017 | 97 | 0.250 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 269 | 0.250 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 964 | 0.240 |
Why?
| | Sirolimus | 2 | 2016 | 192 | 0.220 |
Why?
| | Survival Rate | 5 | 2019 | 1649 | 0.220 |
Why?
| | Pediatrics | 2 | 2020 | 985 | 0.210 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2023 | 446 | 0.210 |
Why?
| | Osteosarcoma | 1 | 2023 | 66 | 0.210 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 139 | 0.200 |
Why?
| | Infant | 10 | 2023 | 7992 | 0.200 |
Why?
| | Male | 22 | 2021 | 56103 | 0.200 |
Why?
| | Antibodies, Monoclonal | 3 | 2016 | 1264 | 0.200 |
Why?
| | Gangliosides | 1 | 2021 | 19 | 0.200 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1177 | 0.190 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4443 | 0.190 |
Why?
| | Female | 22 | 2021 | 60070 | 0.190 |
Why?
| | Whole Genome Sequencing | 1 | 2021 | 110 | 0.190 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2023 | 332 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2014 | 1871 | 0.190 |
Why?
| | Salvage Therapy | 2 | 2019 | 128 | 0.190 |
Why?
| | Bone Neoplasms | 1 | 2023 | 194 | 0.180 |
Why?
| | Necrosis | 2 | 2019 | 211 | 0.180 |
Why?
| | Maximum Tolerated Dose | 3 | 2018 | 182 | 0.180 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2206 | 0.180 |
Why?
| | Receptor, IGF Type 1 | 2 | 2010 | 58 | 0.170 |
Why?
| | Pyridazines | 1 | 2020 | 46 | 0.170 |
Why?
| | Dexamethasone | 2 | 2019 | 315 | 0.160 |
Why?
| | Etoposide | 3 | 2017 | 149 | 0.160 |
Why?
| | Imidazoles | 1 | 2020 | 215 | 0.160 |
Why?
| | Young Adult | 9 | 2022 | 10508 | 0.160 |
Why?
| | Lymphoma | 1 | 2019 | 177 | 0.160 |
Why?
| | Adult | 12 | 2023 | 30814 | 0.160 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 52 | 0.160 |
Why?
| | B7-H1 Antigen | 1 | 2019 | 138 | 0.160 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1127 | 0.150 |
Why?
| | Taxoids | 1 | 2018 | 94 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 153 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 56 | 0.150 |
Why?
| | Heterocyclic Compounds | 1 | 2017 | 20 | 0.140 |
Why?
| | Cetuximab | 1 | 2017 | 90 | 0.140 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2018 | 181 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 524 | 0.140 |
Why?
| | Glucocorticoids | 2 | 2019 | 551 | 0.140 |
Why?
| | Feasibility Studies | 1 | 2019 | 750 | 0.140 |
Why?
| | Azacitidine | 1 | 2017 | 130 | 0.140 |
Why?
| | Myelodysplastic Syndromes | 1 | 2017 | 118 | 0.130 |
Why?
| | Pilot Projects | 1 | 2019 | 1379 | 0.120 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2017 | 532 | 0.120 |
Why?
| | Thyroxine | 1 | 2014 | 59 | 0.110 |
Why?
| | Hypothyroidism | 1 | 2014 | 65 | 0.110 |
Why?
| | Treatment Outcome | 8 | 2022 | 9163 | 0.110 |
Why?
| | DNA Methylation | 1 | 2017 | 502 | 0.110 |
Why?
| | Melanoma | 1 | 2019 | 649 | 0.110 |
Why?
| | Animals | 4 | 2021 | 32158 | 0.110 |
Why?
| | Arsenicals | 1 | 2013 | 24 | 0.110 |
Why?
| | Oxides | 1 | 2013 | 43 | 0.110 |
Why?
| | Leucovorin | 1 | 2012 | 42 | 0.110 |
Why?
| | Organoplatinum Compounds | 1 | 2012 | 40 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 3 | 2019 | 3072 | 0.100 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2022 | 394 | 0.100 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2012 | 310 | 0.100 |
Why?
| | Fluorouracil | 1 | 2012 | 151 | 0.100 |
Why?
| | Spinal Cord | 1 | 2014 | 351 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 319 | 0.100 |
Why?
| | HL-60 Cells | 1 | 2010 | 27 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 78 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 944 | 0.090 |
Why?
| | Brain | 2 | 2014 | 2372 | 0.090 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2010 | 83 | 0.090 |
Why?
| | Infant, Newborn | 3 | 2022 | 5084 | 0.090 |
Why?
| | Drug Synergism | 1 | 2010 | 316 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 935 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 754 | 0.090 |
Why?
| | Pons | 1 | 2009 | 30 | 0.090 |
Why?
| | Methotrexate | 1 | 2010 | 228 | 0.080 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 576 | 0.080 |
Why?
| | Recurrence | 2 | 2010 | 950 | 0.080 |
Why?
| | Doxorubicin | 1 | 2010 | 290 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2009 | 504 | 0.080 |
Why?
| | Molecular Targeted Therapy | 2 | 2022 | 348 | 0.080 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2008 | 99 | 0.080 |
Why?
| | Acute Disease | 1 | 2010 | 917 | 0.080 |
Why?
| | Cell Cycle | 1 | 2010 | 546 | 0.080 |
Why?
| | Drug Design | 1 | 2008 | 156 | 0.070 |
Why?
| | Cell Survival | 1 | 2010 | 1024 | 0.070 |
Why?
| | Cytarabine | 2 | 2017 | 52 | 0.070 |
Why?
| | MAP Kinase Signaling System | 1 | 2008 | 274 | 0.070 |
Why?
| | Genomics | 2 | 2022 | 653 | 0.070 |
Why?
| | Medical Oncology | 1 | 2008 | 230 | 0.070 |
Why?
| | Risk Assessment | 1 | 2015 | 2992 | 0.070 |
Why?
| | Cohort Studies | 3 | 2022 | 4960 | 0.070 |
Why?
| | Mice | 1 | 2021 | 15085 | 0.060 |
Why?
| | Disease Progression | 1 | 2012 | 2423 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2012 | 2581 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2010 | 2196 | 0.060 |
Why?
| | Lactams, Macrocyclic | 1 | 2023 | 46 | 0.050 |
Why?
| | Gene Amplification | 1 | 2023 | 96 | 0.050 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2022 | 40 | 0.050 |
Why?
| | Aminopyridines | 1 | 2023 | 81 | 0.050 |
Why?
| | Oncogenes | 1 | 2022 | 104 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 361 | 0.050 |
Why?
| | Apoptosis | 1 | 2010 | 2377 | 0.050 |
Why?
| | Microtubule-Associated Proteins | 1 | 2022 | 176 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2022 | 12615 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1647 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2022 | 177 | 0.050 |
Why?
| | Drug and Narcotic Control | 1 | 2020 | 29 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2020 | 165 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 296 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 531 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 219 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2022 | 609 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 321 | 0.040 |
Why?
| | Base Sequence | 1 | 2022 | 2121 | 0.040 |
Why?
| | Retreatment | 1 | 2018 | 70 | 0.040 |
Why?
| | Isotretinoin | 1 | 2018 | 22 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 108 | 0.040 |
Why?
| | Azepines | 1 | 2018 | 73 | 0.040 |
Why?
| | Immunotherapy | 1 | 2022 | 481 | 0.040 |
Why?
| | Precision Medicine | 1 | 2021 | 356 | 0.040 |
Why?
| | Hematologic Diseases | 1 | 2018 | 57 | 0.040 |
Why?
| | Daunorubicin | 1 | 2017 | 24 | 0.040 |
Why?
| | Blepharoptosis | 1 | 1997 | 6 | 0.040 |
Why?
| | Benzylamines | 1 | 2017 | 39 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2019 | 621 | 0.040 |
Why?
| | Genes, Dominant | 1 | 1997 | 93 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2018 | 184 | 0.040 |
Why?
| | Treatment Failure | 1 | 2018 | 332 | 0.040 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 1997 | 69 | 0.040 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 78 | 0.040 |
Why?
| | Drug Hypersensitivity | 1 | 2018 | 86 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 184 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 816 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2016 | 114 | 0.030 |
Why?
| | Pyrimidines | 1 | 2018 | 376 | 0.030 |
Why?
| | SEER Program | 1 | 2015 | 195 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 2911 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 533 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2201 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1130 | 0.030 |
Why?
| | United States | 2 | 2022 | 12319 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2270 | 0.030 |
Why?
| | Mutation | 1 | 2023 | 3371 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2013 | 244 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 1227 | 0.030 |
Why?
| | Radiography | 1 | 2014 | 826 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6276 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 286 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2404 | 0.020 |
Why?
| | Radiosurgery | 1 | 2009 | 298 | 0.020 |
Why?
| | Quality of Life | 1 | 2009 | 2390 | 0.010 |
Why?
| | Lod Score | 1 | 1997 | 71 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 1997 | 177 | 0.010 |
Why?
| | Genetic Markers | 1 | 1997 | 336 | 0.010 |
Why?
| | Pedigree | 1 | 1997 | 474 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1997 | 505 | 0.010 |
Why?
| | Genotype | 1 | 1997 | 1830 | 0.010 |
Why?
|
|
Macy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|